This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Patients with hepatitis C without advanced liver disease who achieved sustained virologic response with direct-acting antiviral therapy had significantly reduced all-cause mortality rates compared with both treated patients who did not achieve SVR and untreated patients, according to a recently published data.
“These data strongly support a clinically significant benefit of DAA treatment in patients without clinically apparent advanced liver disease and establishes SVR as a pivotal outcome post DAA treatment specifically in relation to mortality,” Lisa I. Backus, MD, PhD, from the Palo Alto Department of Veterans Affairs, California, and colleagues wrote. “Increasing access to DAAs for all HCV-infected individuals should result in fewer deaths.”